Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign
Open Access
- 2 November 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (11) , e0187466
Abstract
Historically, Neisseria meningitidis serogroup A (NmA) caused large meningitis epidemics in sub-Saharan Africa. In 2010, Burkina Faso became the first country to implement a national meningococcal serogroup A conjugate vaccine (MACV) campaign. We analyzed nationwide meningitis surveillance data from Burkina Faso for the 5 years following MACV introduction. We examined Burkina Faso’s aggregate reporting and national laboratory-confirmed case-based meningitis surveillance data from 2011–2015. We calculated incidence (cases per 100,000 persons), and described reported NmA cases. In 2011–2015, Burkina Faso reported 20,389 cases of suspected meningitis. A quarter (4,503) of suspected meningitis cases with cerebrospinal fluid specimens were laboratory-confirmed as either S. pneumoniae (57%), N. meningitidis (40%), or H. influenzae (2%). Average adjusted annual national incidence of meningococcal meningitis was 3.8 (range: 2.0–10.2 annually) and was highest among infants aged N. meningitidis serogroup W caused the majority (64%) of meningococcal meningitis among all age groups. Only six confirmed NmA cases were reported in 2011–2015. Five cases were in children who were too young (n = 2) or otherwise not vaccinated (n = 3) during the 2010 MACV mass vaccination campaign; one case had documented MACV receipt, representing the first documented MACV failure. Meningococcal meningitis incidence in Burkina Faso remains relatively low following MACV introduction. However, a substantial burden remains and NmA transmission has persisted. MACV integration into routine childhood immunization programs is essential to ensure continued protection.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1084298)
This publication has 25 references indexed in Scilit:
- Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance dataThe Lancet Infectious Diseases, 2016
- Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of AgeClinical Infectious Diseases, 2015
- Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine TrialsClinical Infectious Diseases, 2015
- Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis BeltClinical Infectious Diseases, 2015
- A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan AfricaClinical Infectious Diseases, 2015
- Meeting of the Strategic Advisory Group of Experts on immunization, October 2014 – conclusions and recommendations.2014
- Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd ImmunityClinical Infectious Diseases, 2012
- Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance dataThe Lancet Infectious Diseases, 2012
- Evaluation and Improvement of Real-Time PCR Assays Targeting lytA , ply , and psaA Genes for Detection of Pneumococcal DNAJournal of Clinical Microbiology, 2007
- Use of Real-Time PCR To Resolve Slide Agglutination Discrepancies in Serogroup Identification of Neisseria meningitidisJournal of Clinical Microbiology, 2004